Therapeutic antibody developer Allakos (ALLK -15.7%) is down on almost double normal volume in apparent response to a stream of bearish tweets from Seligman Research related to its just-published report.
The fundamental research shop cites 22 red flags including the lack of KOL validation, minimum sell-side coverage for a company this size, the failure of AK001 (precursor to AK002) and questionable clinical data.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.